P140K-MGMT and G156A-MGMT genes encode two O 6
benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) or O 6 -benzylguanine and temozolomide resistance to primary hematopoietic cells. In this study, we directly compared these and three other O 6 -benzylguanineresistant MGMT genes for their ability to protect the human erythroleukemia cell line, K562, using a direct competitive selection strategy to identify the mutation that conferred the greatest degree of protection from O 6 -benzylguanine and either BCNU or temozolomide. MFG retroviral vector plasmids for each of these mutants [G156A-MGMT (ED 50 for O 6 -benzylguanine, 60 Mmol/L); and P140K-MGMT, MGMT-2 (S152H, A154G, Y158H, G160S, L162V), MGMT-3 (C150Y, A154G, Y158F, L162P, K165R), and MGMT-5 (N157T, Y158H, A170S; ED 50 for benzylguanine, >1,000 Mmol/L)] were mixed, and the virus produced from Phoenix cells was transduced into K562 cells. Stringent selection used high doses of O 6 -benzylguanine (800 Mmol/L) and temozolomide (1,000 Mmol/L) or BCNU (20 Mmol/L) administered twice, and following regrowth, surviving clones were isolated, and the MGMT transgene was sequenced. None of the mutants was lost during selection. Using temozolomide, the enrichment factor was greatest for P140K-MGMT (1.7-fold). Using BCNU selection, the greatest enrichment was observed with MGMT-2 (1.5-fold). G156A-MGMT, which is the least O -benzylguanine plus temozolomide have increased therapeutic efficacy over the chemotherapeutic agents alone in animal tumor xenograft models (1 -8) . Thus, these combinations are currently being evaluated in clinical trials with cutaneous lymphomas, malignant melanoma, brain neoplasms, multiple myeloma, and gastrointestinal carcinomas (9 -12) . However, the damage caused to the bone marrow by these alkylating agents manifests in the short term as myelosuppression or pancytopenia, the dose-limiting toxicity in clinical trials, and has the potential to induce therapy-related myelodysplasia or acute leukemia (13, 14) .
Introduction
Mutations in human MGMT have been developed, which retain AGT activity but are O 6 -benzylguanine resistant. Based on the crystal structure of the AGT active site pocket, it is apparent that these mutants affect the size, hydrophobicity, and flexion of the active site pocket, resulting in exclusion of the benzyl moiety from the active site or a reduction in its ability to undergo an alkyl transfer reaction with the active site cysteine. G156A-MGMT, located within the DNA-binding wing flanking the alkyl-binding pocket (15) , is moderately O 6 -benzylguanine resistant (EC 50 = 60
Amol/L). It distorts the adjacent loop (residues 158 -160) that constitutes one wall of the benzyl-binding pocket (16, 17) . The P140K-MGMT mutant alters the floor of the alkyl-binding pocket, excluding the benzyl group and resulting in a very high degree of O 6 -benzylguanine resistance (EC 50 > 1.2 mmol/L; refs. 18, 19) . Molecular evolution with selection allowed the identification of multiple MGMT mutants highly resistant to O 6 -benzylguanine, which retain the AGT ability to remove alkyl adducts from the O 6 -guanine position in DNA (20) . Three mutants (i.e., MGMT-2, MGMT-3, and MGMT-5), each containing three to five amino acid substitutions in the region of the active site, were the most resistant to O 6 -benzylguanine and BCNU (EC 50 > 2 mmol/L; ref. 20) .
These mutants, O 6 -benzylguanine -resistant MGMT genes, provide a potent selection strategy for drug resistance gene transfer. We have used this for hematopoietic stem cell selection because two chemotherapeutic agents, BCNU, and methylating agents, such as temozolomide, are stem cell toxins, resulting in cumulative stem cell loss and delayed myelosuppression. We first introduced the use of O 6 -benzylguanine -resistant G156A-MGMT to selectively protect the human CD34 cells and suggested that this selective protection could occur while sensitizing the tumor to chemotherapy using O 6 -benzylguanine (21 Retroviral Vectors Retroviral vector pMFG-G156A was constructed to express cDNA sequence for G156A-MGMT as previously described (15) . Retroviral vector pMFG-P140K was constructed to express cDNA sequence for P140K-MGMT by Davis et al. (22) and was originally selected for dual resistance to N-methyl-NV-nitro-N-nitrosoguanidine and O
6
-benzylguanine from a library of AGT mutants containing a random sequence at positions 138 to 140 (18) . Retroviral vectors pMFG-MGMT-2, pMFG-MGMT-3, and pMFG-MGMT-5, containing the following mutations of the MGMT gene, as previously described, MGMT-2 (S152H, A154G, Y158H, G160S, L162V), MGMT-3 (C150Y, A154G, Y158F, L162P, K165R), and MGMT-5 (N157T, Y158H, A170S), were subcloned into MFG retroviral vector (20) . These three MGMT mutant genes were originally selected for dual resistance to N-methyl-NV-nitro-N-nitrosoguanidine and O
-benzylguanine from a library of MGMT mutant genes containing a random sequence at positions 150 to 172 (19) and conferred the greatest degree of resistance to O 6 -benzylguanine and BCNU in K562 cells (20) . Cell Transfections and Transductions DNA from each retroviral vector plasmid was isolated using NucleoBond Plasmid Max kit from Clontech (Palo Alto, CA) and then pooled by mixing 2 Ag of each construct. A total of 10 Ag of retroviral plasmid was transfected into 5 Â 10 6 Phoenix amphotropic packaging cells (a gift from G. Nolon, Stanford University, Stanford, CA), using a calcium phosphate coprecipitation protocol. 4 To transduce K562 cells, these amphotropic producer cells were grown to confluence, and the virus was harvested in DMEM supplemented with 10% heat-inactivated fetal bovine serum. To remove contaminating producer cells, supernatant was filtered through a 0.45-Am filter (Millipore, Bedford, MA). Polybrene was added at 5.5 Ag/mL. K562 cells were infected twice at intervals of 24 hours. The efficiency of transfection and transduction was measured by flow cytometry.
Flow Cytometric Analysis
To determine the MGMT expression in transduced cells, 1 Â 10 6 cells were washed in 2% bovine serum albumin (BSA)/PBS, stabilized for 30 minutes at 4jC using 1% paraformaldehyde (in PBX 1Â), and permeabilized by incubating in 1% Tween 20 (in 2% BSA/PBS) for 30 minutes at 37jC. After permeabilization, cells were washed in 2% BSA/PBS, and nonspecific binding sites were blocked for 30 minutes at 22jC with 10% normal goat serum. AGT antibody mT3.1 (1 Ag) was added, and cells were incubated at 4jC overnight. Cells were washed twice with 2% BSA/PBS and incubated with secondary antibody (goat anti-mouse IgG-1g phycoerytrin conjugated) for 1 hour at 4jC. After washing, cells were resuspended in 300 AL of 2% BSA/PBS for fluorescence-activated cell sorting analysis. Flow cytometry analysis of 10,000 events was done on a FACScan (Becton Dickinson) running CellQuest data acquisition and analysis software (Becton Dickinson). Light scatter was used for gating on permeabilized cells.
Stringent Selection Protocol
High-stringency O -benzylguanine that can be added without slowing cell cycle times (3). After recovery, a second identical treatment was done. Outgrowth before analysis was for 14 days.
Analysis of the Cytotoxic Effects of O 6 -Benzylguanine andTemozolomide Colony-Forming Unit Assay. The O 6 -benzylguanine and BCNU and O 6 -benzylguanine and temozolomide resistance conferred to K562 cells by these five O 6 -benzylguanineresistant MGMT mutants was determined by clonogenic assays. Transfected K562 cells were exposed to increasing doses of temozolomide or BCNU, in the presence or absence of 25 Amol/L O 6 -benzylguanine. After treatment, cells were washed in PBS, and 1,000 cells/mL were plated in triplicate in complete methylcellulose medium (0.8% methylcellulose, 1% BSA, 2 mmol/L L-glutamine, 0.1 mmol/L 1-mercaptoethanol, 10 ng/mL human interleukin-3, and 85 ng/mL human granulocyte macrophage colony-stimulating factor in Iscove's modified Dulbecco's medium; Stem Cell technologies, Vancouver, British Columbia, Canada). One-milliliter samples of the mixture were plated into 35-mm dishes and grown for 10 days. Colonies containing >50 cells was enumerated and compared with parental K562 cells.
PCR Analyses. In four independent experiments, individual colonies picked from methylcellulose cultures were washed with PBS, centrifuged, and then resuspended in 25 to 30 AL of a buffer containing 50 mmol/L Tris-HCl (pH 8), 10 mmol/L EDTA, 100 mmol/L NaCl, and 1% Triton X-100, plus 1 mg/mL proteinase K. The digestion was carried out at 55jC for 2 hours. Proteinase K was inactivated by heating at 95jC for 8 to 10 minutes. Two to five microliters of the digested sample were used for PCR analysis. Amplification was done (after an initial 3 minutes at 95jC) for 35 cycles of 30 seconds at 94jC, 40 seconds at the indicated annealing temperature, and 40 seconds at 72jC. A final extension period of 10 minutes was done. Annealing temperature was 62jC for the MGMT gene and 60jC for the dystrophin gene. Primers for MGMT gene (5V-CTTCACCATCCCGTTTTCCAG-3V and 5V-CTGCCAGACCTGAGCTCCCTC-3V) amplify a 316-bp product; dystrophin primers (5V-TCACTTGCTTGTGCG-CAGG-3V and 5V-GAAAAGTGTATATCAAGGCAGCGAC-GATAA-3V) amplify a 500-bp product. The PCR was done with 40 pmol of each primer, 0.2 mmol/L deoxynucleotide triphosphates, 2 units of Taq polymerase, in a total volume of 50 AL. The PCR products were separated on 1.3% agarose gel and visualized after ethidium bromide staining. The amplified DNA was purified using the QIAquick PCR Purification kit (Qiagen, Valencia, CA) and sequenced to characterize the MGMT gene mutant. Sequence data were analyzed by the MacVector program, version 3.1. The wild-type human MGMT is from Genbank (accession no. NM_002412).
Characterization of the Transduced K562 Cell Population Analysis of Individual K562 Clones. Individual colonies of transduced K562 cells were picked from methylcellulose and cultured in Iscove's modified Dulbecco's medium as above, and cells were harvested for PCR analysis to evaluate the efficiency of the integration of retrovirus DNA. PCR-positive clones were submitted to fluorescenceactivated cell sorting analysis for AGT protein expression as above and to reverse transcription-PCR for mRNA MGMT expression level.
Reverse Transcription-PCR Assay. Total cellular RNA was extracted from 1 Â 10 6 K562 cells with SV total RNA isolation system (Promega, Madison, WI) according to the manufacturer's protocol. Reverse transcription of RNA to cDNA was done according to the protocol of the SuperScript First Strand Synthesis System for reverse transcription-PCR (Life Technologies Bethesda Research Laboratories). For detection of MGMT mRNA, each K562 clone, 10% of the reverse transcriptase reaction with or without reverse transcriptase enzyme, was amplified by PCR with the same thermal cycling profile as above, using 25 cycles. Each PCR was carried out in 25 AL and resolved on a 1.3% agarose gel. (Table 2 ). There is variability among the mutants in protein stability: G156A-MGMT is the least stable.
For transduction into K562 cells, we generated an amphotropic producer cell line by transfecting Phoenix cells with a pool of the five plasmids (pMFG-G156A-MGMT, pMFG-P140K-MGMT, pMFG-MGMT-2, pMFG-MGMT-3, and pMFG-MGMT-5) mixed at equimolar ratios. Twenty-four hours after transfection, 24% of Phoenix + cells expressed these transgenes as determined by flow cytometry using an anti-MGMT antibody (data not shown). After two cycles of transduction, the percentage of K562 cells expressing AGT by flow cytometry was 11% in two independent experiments (data not shown).
MGMT Expression in Clones of Transduced K562 Cells
To understand the results of the competitive selection, we determined the proportion of clones expressing MGMT. K562 clones positive for MGMT by PCR were expanded and MGMT expression analyzed by flow cytometric and reverse transcription-PCR assay. Of 14 MGMT + colonies analyzed by this method, three expressed high levels of AGT protein (89 -96.2%, Fig. 1C -E) , one moderate level (30%, Fig. 1F ), four low level (4 -7%, Fig. 1G -J) , and six clones expressed at very low levels or not at all (1 -2%, Fig. 1K -P) . This analysis was repeated thrice with a total of 48 isolates, and similar results were obtained. Overall, 22% of PCR-positive clones expressed high levels of AGT protein, about 28% expressed low levels, and 43% had undetectable levels of expression.
We next asked whether differences in AGT expression were due to transcriptional activity effects or posttranscriptional events. Reverse transcription-PCR analysis of mRNA showed that the highest level of MGMT mRNA was detected in the clones that express high levels of AGT protein (Fig. 2, lanes C1, C37, and C39) . Much lower levels of MGMT mRNA (Fig. 2, lanes C5, C18, C20 , and C32) were detected for the clones that express 7% to 30% of AGT protein (Fig. 1, C5, C18, C20, and C32) , whereas the absence of MGMT mRNA (Fig. 2, lanes C4, C6, C22 , C24, C26, C27, and C31) was observed in clones with low or absent AGT protein (Fig. 1, C4, C6 , C22, C24, C26, C27, and C31). Therefore, the absence of AGT protein is due to silencing of transcriptional activity and not due to translational effects.
Competitive -benzylguanine resistance to the cell cultures, and a difference between the mutants could not be identified in the survival curves. Cells exposed to temozolomide had increased drug resistance after selection (Fig. 4) . Parental K562 cells had a temozolomide IC 90 < 100 Amol/L, whereas transduced K562 cells had a temozolomide IC 90 of 600 Amol/L. After highstringency O 6 -benzylguanine and temozolomide selection, the temozolomide IC 90 increased to >2,000 Amol/L, 20-fold above untransduced cells. When pretreated with 25 Amol/L benzylguanine, there is no significant difference in the temozolomide IC 90 value. To identify whether there was competitive survival and expansion of K562 clones expressing a particular O 6 -benzylguanine -resistant MGMT mutant and whether this depended on the drug used, we isolated K562 clones from methylcellulose and sequenced the mutant MGMT from sets of clones before and after drug treatment. As shown in Table 3 , a total of 38 clones were sequenced from K562 clones without selection; 55 clones were sequenced after temozolomide selection and 55 clones were sequenced after BCNU selection. In the O 6 -benzylguanine and temozolomide competitive selection studies, P140K-MGMTtransduced cells were enriched 1.7-fold and MGMT-2 was enriched 1.2-fold (P < 0.01, m 2 for the trend in distribution). In the O 6 -benzylguanine and BCNU competitive selection studies, cells transduced with MGMT-2 were enriched 1.5-fold, whereas MGMT-5 was enriched 1.4-fold (P = 0.18, m 2 ).
K562 clones transduced with the two other O

6
-benzylguanine -resistant MGMT mutants (G156A-MGMT and MGMT-3) survived the drug treatment but were underrepresented among the clones isolated and sequenced. The rank order of O 6 -benzylguanine -resistant MGMT mutants selected under these enrichment conditions differed after temozolomide compared with BCNU selection. In addition, the selection pressure for temozolomide seemed greater than with BCNU because the range of enrichment between -benzylguanine (O 6 -BG ) and BCNU resistance conferred to MGMT -transduced K562 cells before and after high-stringency selection. K562 cells were treated with BCNU alone (5, without selection; n, after selection) or O 6 -benzylguanine and BCNU (4, without selection; E, after selection). Cells were exposed to 25 Amol/L O 6 -benzylguanine for 1 h followed with 0 to 80 Amol/L of BCNU. As a control, we measured the sensitivity of parental K562 cells to BCNU (.). K562 cells were plated at 1,000 per dish. After 10 to 12 d, colonies were enumerated.
the O 6 -benzylguanine -resistant MGMT mutants was 4.9-fold with temozolomide but only 2.1-fold with BCNU. This may represent both intrinsic properties of drug selection and the dose intensity used.
Discussion
In this study, we compared the in vitro efficacy of five O 6 -benzylguanine -resistant MGMT mutants in protecting K562 cells against cytotoxicity induced by temozolomide and BCNU. We found that competitive, high-stringency drug selection identified the most potent drug-resistant MGMT mutant, and that this O 6 -benzylguanine -resistant MGMT mutant differed, depending on the drug used. The competitive in vitro selection and regrowth strategy is more discriminating than a simple survival assay and has been used to identify other drug resistance mutants, such as thymidine kinase (23), thymidylate synthase (24) , dihydrofolate reductase (25) , and glutathione S-transferase (26).
Our primary goal was to determine whether any of the five O 6 -benzylguanine -resistant MGMT mutants would be lost during selection, and whether we could actually select from among these remarkably O 6 -benzylguanine -resistant mutant proteins during high-dose O 6 -benzylguanine exposure and drug treatment. We hypothesized that G156A-MGMT might be lost because it is less O 6 -benzylguanine resistant, but it was not. Because all of the remaining four MGMT mutants are highly O 6 -benzylguanine resistant, we might not have observed any selection. Instead, we found that after selection with O 6 -benzylguanine and temozolomide, the most highly enriched mutant was P140K-MGMT, with an enrichment factor of 1.7 fold (P = 0.01). In contrast, resistance to O 6 -benzylguanine and BCNU resulted in enrichment in favor of MGMT-2 and MGMT-5 by 1.5-and 1.4-fold, respectively. This selection only reached P = 0.18; thus, the selection was quite modest compared with O 6 -benzylguanine and temozolomide. MGMT-2 and MGMT-5 also proved to be the most O
6
-benzylguanine -resistant MGMT mutants in our previous study, where 11 different MGMT multiple mutants (20) , not including P140K-MGMT and G156A-MGMT, were competed, and the enrichment factor for MGMT2 and MGMT5 was 10-and 6-fold, respectively. This study confirms those results.
One factor that might skew the results is to have one of the O 6 -benzylguanine -resistant MGMT mutants transcribed or expressed at lower levels. This might overwhelm the ability to compete against another of the mutants. We analyzed this and found a similar distribution of gene expression and protein production among the mutants. On the other hand, the variation in viral production was not a factor because we analyzed the relative not the absolute enrichment after drug selection.
It is of interest that the P140K-MGMT mutant came in first with temozolomide and third during selection with O 6 -benzylguanine and BCNU. Intrinsic properties of the various O 6 -benzylguanine -resistant MGMT mutants likely contribute to the selection competition. The MGMT-3 mutant is the most stable of the mutant AGTs (19, 20) . Stability and expression levels are important for repair of Figure 4 . Comparison of the O 6 -benzylguanine (O 6 -BG ) and temozolomide (TMZ ) resistance conferred to MGMT-transduced K562 cells before and after high-stringency selection. K562 cells were treated with temozolomide alone (5, without selection; n, after selection) or O 6 -benzylguanine and temozolomide (4, without selection; E, after selection). Cells were exposed to O 6 -benzylguanine (25 Amol/L) for 1 h before increasing doses of temozolomide (200 -2,000 Amol/L). As a control, we measured the sensitivity of parental K562 cells (.) to temozolomide. K562 cells were plated at 1,000 per dish. After 10 to 12 d, colonies were enumerated. -benzylguanine -resistant MGMT mutant recovered from K562 clones from unselected cultures and after either temozolomide or BCNU selection. Fold enrichment is the ratio of the proportion of recovered colonies in the selected versus unselected cohorts. The m 2 for the distributions indicated P < 0.01 for the change in distribution after temozolomide and P = 0.18 for the change in distribution after BCNU. A total of 38 clones were analyzed from the unselected cultures and 55 each from the cultures selected with temozolomide and O 6 -methylguanine adducts generated by temozolomide because large numbers of adducts are formed, and removal of most of these adducts is required to protect the cell (27) . In contrast, smaller numbers of BCNU-directed cross-links kill the cell; thus, a few highly O 6 -benzylguanine-resistant molecules of AGT are sufficient, whereas stability and total expression level are less important. The fact that the G156A-MGMT mutant, whereas not the most potent, was not lost during either competitive drug selection suggests that the degree of O 6 -benzylguanine resistance and protein stability are sufficient to repair DNA lesions in cells. This result is consistent with the ability of G156A-MGMT to protect CD34 cells in vitro (21), LTC-IC (28, 29) , murine repopulating progenitor cells transplanted in vivo (30, 31) , to increase the therapeutic efficacy of O -chloroethylguanine adducts on DNA. Surprisingly, G156A-MGMT was not lost during the competition study, and it shows the relative potency of G156A-MGMT in repair either O
-methylguanine or O 6 -chloroethylguanine lesions in DNA. Moreover, although P140K-MGMT was not preferred in the direct competition for O 6 -benzylguanine and BCNU resistance, it is a stable AGT protein (22) and has shown efficacy as an O 6 -benzylguanine and BCNU resistance gene protecting murine progenitor cells (35) in vitro and in vivo and in a dose-intensive tumor xenograft (36) .
In summary, we have developed a direct competitive selection approach to analyze O 6 -benzylguanine -resistant MGMT mutant enrichment after selection with either O 6 -benzylguanine and temozolomide or O 6 -benzylguanine and BCNU. This approach can detect differences not seen in comparative clonal survival curves. We find that P140K-MGMT is preferred during O 6 -benzylguanine and temozolomide selection, whereas the multiple amino acidsubstituted MGMT-2 is slightly (P = 0.18) preferentially enriched after O 6 -benzylguanine and BCNU. However, even the moderately O 6 -benzylguanine -resistant mutant G156A-MGMT is not lost. This suggests that MGMT-2, in particular, should be added to the list of effective O 6 -benzylguanine -resistant MGMT mutants that would be useful during drug resistance gene transfer into hematopoietic stem cells, and that the choice of O 6 -benzylguanine -resistant MGMT mutant should depend on the drug selection anticipated.
